Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors

At least one compound chosen from compounds of Formula (I):

• and pharmaceutically acceptable salts thereof, wherein
• R1 is chosen from H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 haloalkyl, C2-8 haloalkenyl, and C2-8 haloalkynyl groups;
• R2 is chosen from —OH, —NH2, —OC(═O)Y1, —NHC(═O)Y1, and —NHC(═O)NHY1 groups, wherein Y1 is chosen from C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 haloalkyl, C2-8 haloalkenyl, C2-8 haloalkynyl, C6-18 aryl, and C1-13 heteroaryl groups;
• R3 is chosen from —CN, —CH2CN, and —C(═O)Y2 groups, wherein Y2 is chosen from C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, —OZ1, —NHOH, —NHOCH3, —NHCN, and —NZ1Z2 groups, wherein Z1 and Z2, which may be identical or different, are independently chosen from H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 haloalkyl, C2-8 haloalkenyl, and C2-8 haloalkynyl groups, wherein Z1 and Z2 may join together to form a ring;
• R4 is chosen from C3-8 cycloalkyl groups;
• each R5 is independently chosen from H, halo, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 haloalkyl, C2-8 haloalkenyl, and C2-8 haloalkynyl groups, with the proviso that at least one R5 is not H;
• n is chosen from integers ranging from 1 to 4;
• and
• Linker is chosen from linker groups.